There was no apparent expression of Wnt3a and Wnt5a in these cell lines

eristics at baseline were compared by independent samples t-test for continuous variables and Fisher’s exact test for dichotomous variables. Changes in outcome parameters were evaluated including only patients who completed the full 24 weeks by independent samples t-test. Multiple linear Cobicistat site regression analysis was applied to compare the changes in the two groups with adjustment for the baseline values of the particular variable. Finally additional multiple regression analyses were carried out to investigate the influence of parameters known to influence arterial stiffness. Laboratory data were pooled for control visits in order to investigate differences between groups during the stable treatment regime. Data are presented as mean with standard deviations or with 95% confidence intervals for mean. Urinary albumin excretion was skewed and therefore log-transformed prior to analysis. Baseline data are presented as geometric means with 95%CI, and changes are presented as ratios with 95%CI. Data were analyzed using SPSS statistical software, version 20. Patient characteristics Fifty-four patients were included, and 46 completed the study. Three patients were withdrawn by the investigator prior to the first visit due to unexpected serious non-renal disease. Five patients did not complete the study, four in the eplerenone group and one in the control group. In the eplerenone group, three patients were withdrawn due to possible side effects: one due to recurrence of gout, one due to a feeling of swollenness of the tongue and one patient due to nausea, dizziness and general discomfort. The last withdrawal in the eplerenone group was caused by other serious non-renal disease resulting in acute renal failure. In the control group, one patient was withdrawn due to a relapse of glomerulonephritis. This left 22 patients in the eplerenone group and 24 patients in the control group. Unfortunately, it proved not possible to recruit the full planned number of patients within the time frame and resources allotted to the study. There were no differences in demographic data, and baseline values of vascular and laboratory data were comparable between the groups. Quality of measurements Results Patients were recruited consecutively from April 2010 through June 2011. No patients had had both stroke and MI. All P-values.0.05. No conversion necessary for p-potassium or pbicarbonate in mEq/L and mmol/L. AASI, Ambulatory Arterial Stiffness Index; AIx, Augmentation Index; AIx@HR75, Augmentation Index adjusted for heart rate 75 beats/minute; BP, blood pressure; cfPWV, carotid-femoral pulse wave velocity; eGFR, estimated glomerular filtration rate; Indices of arterial stiffness are a mean of two measurements per patient, except AASI. 24 h urinary albumin excretion is presented as geometric means with 95% CI. All P-values.0.05. Blood Pressure and heart rate The 24 h systolic BP fell in the eplerenone group by 4.7 mmHg, and in the control group by 1.3 mmHg. The difference between changes in the groups was 3 mmHg, P = 0.2. The 24 h diastolic BP, office systolic and diastolic BPs, central BPs, as well as office BPs at control visits did not differ 24347635 significantly between the eplerenone and control group. Mean HR at baseline was 63 beats/min, in the eplerenone group and 64 in the control group, P = 0.8. There were no significant changes between groups, P = 0.4. Mean 24 h HR at baseline was 71 beats/min in the eplerenone group and 69, in the control group, P = 0.4. 26028783 There were